ARM Press Release

Alliance for Regenerative Medicine Releases Q2 2015 Data Report, Highlighting Sector Trends and Metrics

WASHINGTON, DC, July 29, 2015 – The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, today announced the release of a new data report, offering an in-depth look at sector trends and metrics from the months April through June 2015.

Using information provided by ARM’s data partner Informa, the quarterly report details sector-specific statistics compiled from more than 580 leading companies worldwide, including total financings, corporate partnerships and acquisitions, clinical trial information, data events and ARM’s current regulatory and advocacy priorities. 

New in this report is a section specifically highlighting European region performance during the first half of 2015, including sector commentary from GE Healthcare Life Sciences President and CEO Kieran Murphy, along with region-specific financing data by technology type.

The report also features commentary from several ARM member company executives, including Cellular Dynamics International; Editas Medicine; Green Cross Holdings; Memorial Sloan Kettering Cancer Center; Novartis AG; StemCells, Inc.; and uniQure.

“The second quarter of 2015 continued the trend of steady growth sector-wide,” said Morrie Ruffin, managing director ARM. “We saw an impressive number of significant collaborations and deals in the past few months, a trend we expect will continue throughout 2015, highlighting the robust activity and progress happening in this space.”
Highlighted findings from the second quarter report include:

• Globally, companies in the combined regenerative medicine and advanced therapies field raised more than $4.9 billion in the second quarter of 2015 and $7.6B in the first half of 2015, up 129 and 137 percent, respectively, compared to the same time periods last year. The report also includes additional information by technology focus area and financing type.
• In the European region this year, regenerative medicine and advanced therapies companies raised $1.5 billion in the first half of 2015, up 183% compared to the first half of 2014.
• There were 528 clinical trials underway worldwide at the end of second quarter 2015, with 169 in Phase I, 304 in Phase II and 55 in Phase III.
• ARM’s current regulatory and legislative priorities include the implementation of a federally-directed U.S. national strategy for regenerative medicine and advanced therapies, along with the establishment of a Standards Coordinating Body; improving and facilitating the use of FDA incentive programs for Qualified Regenerative Medicine Products; improved communication and coordination among FDA review centers; the creation and implementation of reimbursement coverage and coding policies for regenerative medicine and advanced therapies products; reviewing and submitting comments to the European Medicines Agency’s draft guidelines regarding gene therapy medicinal products; and continuing to monitor discussions of the ATMP regulation and implementation across EU member states.

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, along with key financial and data events.

The report is available online here. For more information, please visit alliancerm.org or contact ARM’s Communications Director Lyndsey Scull at lscull@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

###